Key result
The simultaneous elevation of all four inflammatory biomarkers (IL-1β, IL-18, IL-6, and hsCRP) was associated with an increased risk of major adverse cardiac and cerebrovascular events.
Why the study?
Does a combined, pathway-informed inflammatory biomarker panel improve prognostic risk assessment for major adverse cardiovascular events in patients with multivessel coronary disease post-PCI?
Does a combined, pathway-informed inflammatory biomarker panel improve prognostic risk assessment for major adverse cardiovascular events in patients with multivessel coronary disease post-PCI?
Answers are grounded in this paper and cite their sources.
A combined biomarker assessment spanning the NLRP3 inflammasome pathway (IL-1β, IL-18, IL-6, and hsCRP) provides a more comprehensive and prognostically valuable measure of residual inflammatory risk in multivessel coronary disease than single biomarkers.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted an editorial in Multivessel coronary disease (MVD) (n=1,058). Combined elevation of four inflammatory biomarkers (IL-1β, IL-18, IL-6, and hsCRP) vs. No elevated biomarkers was evaluated on 4-component major adverse cardiac and cerebrovascular event (MACCE-4P: all-cause death, myocardial infarction, stroke, or revascularization) (HR 2.64). The simultaneous elevation of all four inflammatory biomarkers (IL-1β, IL-18, IL-6, and hsCRP) was associated with an increased risk of major adverse cardiac and cerebrovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: